Executive summary “Depression is a disorder of mood, so mysteriously painful and elusive
in the way it becomes known to the self—to the mediating intellect—as to verge close to …

Background Psilocybin is being studied for use in treatment-resistant depression. Methods
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …

Background In treatment-resistant depression, commonly defined as a lack of response to
two or more consecutive treatments during the current depressive episode, the percentage …

Background Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are
both currently used for treatment-resistant major depression, but the comparative …

Objective: Estimates of prevalence and burden of treatment-resistant depression (TRD) vary
widely in the literature. This study evaluated the prevalence and burden of TRD and the …

Objectives: To provide advice and guidance regarding the management of mood disorders,
derived from scientific evidence and supplemented by expert clinical consensus to formulate …

For many years, psychiatrists have tried to understand factors involved in response to
medications or psychotherapies, in order to personalize their treatment choices. There is …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

A promising new treatment approach for major depressive disorder (MDD) targets the
microbiota-gut-brain (MGB) axis, which is linked to physiological and behavioral functions …

Some recent clinical and preclinical evidence suggests that neuroinflammation is a key
factor that interacts with the three neurobiological correlates of major depressive disorder …